Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine

Molecular and Cellular Biochemistry

Volumn 370, Issue 1-2, 2012, Pages 199-207

  Rice, Kevin P ^a   Klinkerch, Edmund J ^a   Gerber, Scott A ^b   Schleicher, Tyler R ^a,c   Kraus, Tara J ^a   Buros, Christopher M ^a  

^a Health Services and Department of Biology   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Alkylating agents; Laromustine; Methyl isocyanate; Thioredoxin reductase

Indexed keywords

GLUTATHIONE REDUCTASE; LAROMUSTINE; THIOREDOXIN REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBAMOYLATION; CELL LYSATE; CONTROLLED STUDY; IN VITRO STUDY; MASS SPECTROMETRY; NONHUMAN; RAT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAMATES; CARMUSTINE; CELL LINE, TUMOR; CYSTEINE; DRUG SCREENING ASSAYS, ANTITUMOR; HYDRAZINES; HYDROGEN-ION CONCENTRATION; ISOCYANATES; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; RATS; SULFONAMIDES; TANDEM MASS SPECTROMETRY; THIOREDOXIN-DISULFIDE REDUCTASE; TIME FACTORS;

MURINAE; RATTUS;

EID: 84867332189     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1411-y     Document Type: Article

References (57)

1. Baumann RP, Seow HA, Shyam K, Penketh PG, Sartorelli AC (2005) The antineoplastic efficacy of the prodrug cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res 15:313-325
2. Finch RA, Shyam K, Penketh PG, Sartorelli AC (2001) 1,2- Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101 M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 61:3033-3038
3. Ishiguro K, Seow HA, Penketh PG, Shyam K, Sartorelli AC (2006) Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther 5:969-976
4. Penketh PG, Shyam K, Baumann RP, Remack JS, Brent TP, Sartorelli AC (2004) 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl] hydrazi ne (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol 53:279-287
5. Penketh PG, Baumann RP, Ishiguro K, Shyam K, Seow HA, Sartorelli AC (2008) Lethality to leukemia cell lines of DNA interstrand cross-links generated by cloretazine derived alkylating species. Leuk Res 32:1546-1553
6. Baumann RP, Shyam K, Penketh PG, Remack JS, Brent TP, Sartorelli AC (2004) 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl] hydrazi ne (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother Pharmacol 53:288-295
7. Frederick AM, Davis ML, Rice KP (2009) Inhibition of human DNA polymerase beta activity by the anticancer prodrug cloretazine. Biochem Biophys Res Commun 378:419-423
8. Eisenbrand G, Muller N, Denkel E, Sterzel W (1986) DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitrosocompounds. J Cancer Res Clin Oncol 112:196-204
9. Gombar CT, Tong WP, Ludlum DB (1980) Mechanism of action of the nitrosoureas-IV. Reactions of bis-chloroethyl nitrosourea and chloroethyl cyclohexyl nitrosourea with deoxyribonucleic acid. Biochem Pharmacol 29:2639-2643
10. Abushamaa AM, Sporn TA, Folz RJ (2002) Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am J Physiol Lung Cell Mol Physiol 283:L336-L345
11. Johnston TP, Montgomery JA (1986) Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems. Cancer Treat Rep 70:13-30
12. Gibson NW, Hickman JA (1982) The role of isocyanates in the toxicity of antitumour haloalkylnitrosoureas. Biochem Pharmacol 31:2795-2800
13. Rice KP, Penketh PG, Shyam K, Sartorelli AC (2005) Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs cloretazine and BCNU. Biochem Pharmacol 69:1463-1472
14. Slatter JG, Davis MR, Han DH, Pearson PG, Baillie TA (1993) Studies on the metabolic fate of caracemide, an experimental antitumor agent, in the rat. Evidence for the release of methyl isocyanate in vivo. Chem Res Toxicol 6:335-340
15. Kestell P, Gledhill AP, Threadgill MD, Gescher A (1986) S-(N-methylcarbamoyl)-N-acetylcysteine: a urinary metabolite of the hepatotoxic experimental antitumour agent N-methylformamide (NSC 3051) in mouse, rat and man. Biochem Pharmacol 35:2283-2286
16. Moriarty-Craige SE, Jones DP (2004) Extracellular thiols and thiol/disulfide redox in metabolism. Annu Rev Nutr 24:481-509
17. Meister A (1994) Glutathione-ascorbic acid antioxidant system in animals. J Biol Chem 269:9397-9400
18. Smith AC, Boyd MR (1984) Preferential effects of 1,3-bis(2-chloroethyl)- 1-nitrosourea (BCNU) on pulmonary glutathione reductase and glutathione/ glutathione disulfide ratios: possible implications for lung toxicity. J Pharmacol Exp Ther 229:658-663
19. Holmgren A, Bjornstedt M (1995) Thioredoxin and thioredoxin reductase. Methods Enzymol 252:199-208
20. Mustacich D, Powis G (2000) Thioredoxin reductase. Biochem J 346(Pt 1):1-8
21. Holmgren A, Lu J (2010) Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 396:120-124
22. Powis G, Montfort WR (2001) Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41:261-295
23. Arner ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102-6109
24. Liu Y, Min W (2002) Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 90:1259-1266
25. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17:2596-2606
26. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, Gius D (2007) Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharm Des 13:3368-3377
27. Urig S, Becker K (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 16:452-465
28. Zeng HH, Wang LH (2010) Targeting thioredoxin reductase: anticancer agents and chemopreventive compounds. Med Chem 6:286-297
29. Arner ES, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16:420-426
30. Conrad M (2009) Transgenic mouse models for the vital selenoenzymes cytosolic thioredoxin reductase, mitochondrial thioredoxin reductase and glutathione peroxidase 4. Biochim Biophys Acta 1790:1575-1585
31. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281:13005-13008
32. Turanov AA, Kehr S, Marino SM, Yoo MH, Carlson BA, Hatfield DL, Gladyshev VN (2010) Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem J 430:285-293
33. Mandal PK, Schneider M, Kolle P, Kuhlencordt P, Forster H, Beck H, Bornkamm GW, Conrad M (2010) Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 70:9505-9514
34. Anestal K, Prast-Nielsen S, Cenas N, Arner ES (2008) Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS ONE 3:1-16
35. Williams CH, Arscott LD, Muller S, Lennon BW, Ludwig ML, Wang PF, Veine DM, Becker K, Schirmer RH (2000) Thioredoxin reductase two modes of catalysis have evolved. Eur J Biochem 267:6110-6117
36. Cheng Q, Sandalova T, Lindqvist Y, Arner ES (2009) Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 284:3998-4008
37. Nordberg J, Zhong L, Holmgren A, Arner ES (1998) Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J Biol Chem 273:10835-10842
38. Papp LV, Lu J, Holmgren A, Khanna KK (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9:775-806
39. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39:696-703
40. Shyam K, Penketh PG, Divo AA, Loomis RH, Patton CL, Sartorelli AC (1990) Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J Med Chem 33:2259-2264
41. Shyam K, Penketh PG, Loomis RH, Rose WC, Sartorelli AC (1996) Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines. J Med Chem 39:796-801
42. Kettenbach AN, Gerber SA (2011) Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments. Anal Chem 83:7635-7644
43. Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4:rs5
44. Eng JK, McCormack AL, Yates JR (1994) An approach to correlate tandem mass-spectral data of peptides with amino-acid-sequences in a protein database. J Am Soc Mass Spectrom 5:976-989
45. Faherty BK, Gerber SA (2010) MacroSEQUEST: efficient candidate-centric searching and high-resolution correlation analysis for large-scale proteomics data sets. Anal Chem 82:6821-6829
46. Schallreuter KU, Gleason FK, Wood JM (1990) The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim Biophys Acta 1054:14-20
47. Seyfried J, Wullner U (2007) Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: role of glutathione and the MKK4/JNK pathway. Biochem Biophys Res Commun 359:759-764
48. Lan L, Zhao F, Wang Y, Zeng H (2007) The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear factor-kappaB-dependent pathway. Eur J Pharmacol 555:83-92
49. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42:872-881
50. Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17:297-303
51. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Feau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ (2011) An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20:384-399
52. Bednar F, Simeone DM (2012) Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res (Phila) 5:351-354
53. Arteaga CL, Baselga J (2012) Impact of genomics on personalized cancer medicine. Clin Cancer Res 18:612-618
54. Lin SH, Kleinberg LR (2008) Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8:343-359
55. Penketh PG, Shyam K, Sartorelli AC (2000) Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol 59:283-291
56. Murren J, Modiano M, Kummar S, Clairmont C, Egorin M, Chu E, Sznol M (2005) A phase I and pharmacokinetic study of VNP40101 M, a new alkylating agent, in patients with advanced or metastatic cancer. Invest New Drugs 23:123-135
57. Raizer J, Rice L, Rademaker A, Chandler J, Levy R, Muro K, Grimm S (2011) A phase I trial of laromustine (VNP40101 M) and temozolomide for patients with malignant gliomas in first relapse or progression. Neuro Oncol 13:60-61